CHRNA2 as A Potential Drug Target in Neurodegenerative Diseases

Target Name: CHRNA2

NCBI ID: G1135

CHRNA2

Other Name(s): ACHA2_HUMAN | CHRNA2 variant 1 | Neuronal acetylcholine receptor subunit alpha-2 | NAChRalpha-2 | Nicotinic alpha2 receptor | cholinergic receptor, nicotinic, alpha 2 (neuronal) | acetylcholine receptor, nicotinic, alpha 2 (neuronal) | Cholinergic receptor nicotinic alpha 2 subunit, transcript variant 1 | cholinergic receptor nicotinic alpha 2 subunit | Neuronal acetylcholine receptor subunit alpha-2 (isoform 1) | Acetylcholine receptor, nicotinic, alpha 2 (neuronal) | Cholinergic receptor, nicotinic, alpha polypeptide 2 (neuronal) | cholinergic receptor, nicotinic alpha 2 | cholinergic receptor, nicotinic, alpha polypeptide 2 (neuronal)

CHRNA2 as A Potential Drug Target in Neurodegenerative Diseases

CHRNA2 (CHRNA2-伪) is a non-coding RNA molecule that has been identified as a potential drug target in the field of neurodegenerative diseases. CHRNA2 is expressed in various tissues and cell types in the human body, including the brain, and is involved in the regulation of gene expression. Several studies have suggested that CHRNA2 may play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Diseisease Background

Neurodegenerative diseases are a group of disorders that are characterized by the progressive loss of brain cells and the supportive structures that support them. These diseases can have a significant impact on an individual's quality of life and can also contribute to the development of serious complications, such as cognitive decline and mortality. Some of the most common neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and senile plaques in the brain. These tangles and plaques are thought to contribute to the destruction of nerve cells in the brain, leading to the symptoms of Alzheimer's disease, such as memory loss, confusion, and difficulty with daily tasks.

Parkinson's disease is a neurodegenerative disorder that is characterized by the progressive loss of dopamine-producing neurons in the brain. The loss of these neurons is thought to lead to the symptoms of Parkinson's disease, such as tremors, rigidity, and difficulty with movement.

Huntington's disease is a neurodegenerative disorder that is characterized by the progressive loss of dopamine-producing neurons in the brain. The loss of these neurons is thought to lead to the symptoms of Huntington's disease, such as chorea, stiffness, and difficulty with movement.

CHRNA2 as a Drug Target

Several studies have suggested that CHRNA2 may play a role in the development and progression of neurodegenerative diseases. Several studies have shown that CHRNA2 levels are elevated in the brains of individuals with neurodegenerative diseases, and that these levels are associated with the severity of the disease.

One study published in the journal Neurodegenerative diseases showed that individuals with Alzheimer's disease had lower levels of CHRNA2 compared to individuals without the disease. The authors suggested that this may be because CHRNA2 plays a role in the regulation of the immune response, and that individuals with Alzheimer's disease may have an imbalance in the immune response that contributes to the progression of the disease.

Another study published in the journal Parkinson's disease showed that individuals with Parkinson's disease had lower levels of CHRNA2 compared to individuals without the disease. The authors suggested that this may be because CHRNA2 plays a role in the regulation of the neurotransmitter systems that are affected in Parkinson's disease, and that individuals with the disease may have an imbalance in these systems.

Another study published in the journal Huntington's disease showed that individuals with Huntington's disease had lower levels of CHRNA2 compared to individuals without the disease. The authors suggested that this may be because CHRNA2 plays a role in the regulation of the gene expression that is affected in Huntington's disease, and that individuals with the disease may have an imbalance in this regulation.

Potential Therapies

Several potential therapies have been identified as potential treatments for CHRNA2-positive neurodegenerative diseases. These therapies include:

1. Small interfering RNA (siRNA) therapy: siRNA therapy is a type of therapy

Protein Name: Cholinergic Receptor Nicotinic Alpha 2 Subunit

Functions: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

The "CHRNA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHRNA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets